NO.1 中国首个获批治疗PFIC的非手术靶向药物上市 近日,益普生宣布其罕见病创新药“蓓尔唯”(通用名:奥德昔巴特胶囊)在中国正式商业上市。去年12月,该药物在国内获批用于治疗≥6月龄的PFIC患者的瘙痒,是目前中国首个且唯一获批治疗PFIC领域的非手术靶向药物,目前已被纳入3个省市惠民保国内特药目录及11个省市惠民保海外特药目录。 点评:PFIC是一种罕见的遗传性疾病,发病率为(1~2)/...
Source LinkNO.1 中国首个获批治疗PFIC的非手术靶向药物上市 近日,益普生宣布其罕见病创新药“蓓尔唯”(通用名:奥德昔巴特胶囊)在中国正式商业上市。去年12月,该药物在国内获批用于治疗≥6月龄的PFIC患者的瘙痒,是目前中国首个且唯一获批治疗PFIC领域的非手术靶向药物,目前已被纳入3个省市惠民保国内特药目录及11个省市惠民保海外特药目录。 点评:PFIC是一种罕见的遗传性疾病,发病率为(1~2)/...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.